Valuation of Compensation for Healthcare Services: Medical Director Compensation
(Part Four of a Four-Part Series)

In the face of uncertain reimbursement, the rising costs of healthcare services, and value-seeking reforms pushing for higher quality care at lower prices, providers are turning to alignment, integration, and cooperation as key strategies to create high-quality and high-efficiency healthcare delivery organizations. This trend is resulting in the increased corporatization of medicine, including a greater number of physicians being employed by hospitals. Concurrently, there has been a parallel growth in the number of hospitals compensating physicians for their performance of hospital administrative functions, including medical directorships. Corresponding with the increase in the corporatization of medicine, governmental authorities have engaged in heightened regulatory scrutiny related to the legal permissibility of these arrangements, including whether physicians are actually performing the services outlined in the relevant medical directorship agreement.

In light of the aforementioned trends that are creating a paradigm shift in the healthcare delivery system, it is important that valuation analysts ensure that the subject medical director services are appropriately classified and valued in order to provide a defensible opinion for their clients. This final installment in the four-part Health Capital Topics series on the classification and valuation of compensation for healthcare services will provide a brief overview of this process for medical director services.

There are numerous variations within the classification of medical director services, including:

1. **Medical Director, General**: Generally responsible for all activities related to the delivery of medical care and clinical services, such as cost management, utilization review, quality assurance, and medical protocol development, as well as overseeing the activities of group physicians, including recruiting and credentialing.

2. **Service Line Medical Director**: Similar to a “Medical Director, General” but specific to a particular clinical service line (e.g., cardiology, orthopedics).

3. **Medical Director of Clinical Research**: Responsible for:
   - (a) Research design, methodology, data collection, analysis, and summation of outcomes;
   - (b) Grant proposal preparation;
   - (c) Attending research conferences;
   - (d) Compliance with protocols, regulations, and research objectives; and,
   - (e) Serving as a liaison between funding agencies and the organization.

4. **Medical Director of Clinical Operations**: Responsible for:
   - (a) Monitors day-to-day operations;
   - (b) Develops, implements, and monitors policies/procedures;
   - (c) Oversees non-physician technical and records staff; and,
   - (d) Responsible for improving quality and reducing cost by streamlining workforce and technology.

5. **Medical Director of Quality Management**: Responsible for:
   - (a) Resolving medical practice issues;
   - (b) Advising the corporate office on the legal, ethical, and financial issues related to the medical staff;
   - (c) Resolving the medical practice issues prior to any legal action;
   - (d) Resolving the medical practice issues upon request of the medical staff; and,
   - (e) Resolving the medical practice issues prior to any legal action.

The alignment, integration, and engagement of physicians are key strategies for health systems seeking to create high-performing, high-quality, and high-efficiency organizations. Yet aligning physicians’ interests with those of hospitals and health systems has been an ongoing struggle, particularly due to the shift from small, physician/provider-owned, independent private practices to captive practices within larger integrated health systems, i.e., the corporatization of the practice of medicine. Successful hospital enterprises have understood that “to effectively respond to the economic incentives of reform, a hospital should achieve a deeper level of integration with the physicians that practice there.” This has also been a factor in using professionals with “inside knowledge” of the health system, as well as the collegial “doctor-to-doctor” relationship with fellow physicians on the medical staff, to perform administrative, management, or executive services within the organization in an enhanced, efficient manner.

The economic value analysis for determining the fair market value (FMV) of medical director services is
governed by the economic principles of Utility and Substitution.\(^5\) Similar to compensation arrangements that include physician clinical services (which were discussed in Part One of this four-part series), in the past, compensation for medical director services performed by physicians may have been based on the physician’s historical clinical practice earnings.\(^6\) However, there is increasing concern that compensating medical directors based on a lost “opportunity cost” may not meet regulatory scrutiny under the Stark Law, and should instead be based on the actual services performed.\(^7\) (For a further discussion on this topic, see the December 2014 Health Capital Topics article, entitled, “Threshold of Commercial Reasonableness: The Qualitative Analysis”.)

In particular, courts are evaluating, under the Stark Law and Anti-Kickback Statute, whether physician medical directors are actually performing the services outlined in the agreement. For example, in U.S. v. SCCI Hospital Houston, the U.S. challenged the commercial reasonableness of the compensation paid by the hospital to three physician medical directors.\(^8\) The government’s financial expert stated that the commercial reasonableness of a medical director arrangement depended upon the agreement being “essential to the functioning of the hospital,”\(^9\) and emphasized that there had to be “sound business reasons for paying medical director fees to referring physicians.”\(^10\) To examine these thresholds, the government’s expert analyzed several factors in assessing the commercial reasonableness of the compensation agreement, including:

1. The size of the hospital, number of patients, patient acuity levels, and patient needs;
2. The quality of activities and involvement of medical staff in need of medical direction;
3. The number of regular committees and meetings requiring physician involvement; and,
4. The quality of hospital management and interdisciplinary coordination of patient services.\(^11\)

While medical director compensation may be based on either: (1) an hourly payment, with the maximum number of hours specified in the contract; or, (2) an annual payment that is determined by a projected number of hours multiplied by a hourly rate consistent with FMV, it may be critical to surviving regulatory scrutiny for the employer to track and document the actual number of hours the medical director spends performing each of the services outlined in the agreement.\(^12\)

In developing a certified opinion of value related to the provision of medical directorship services, certain requisite documents related to the proposed arrangement(s) should be obtained by the valuation analyst, including:\(^13\)

1. The proposed agreement(s) for administrative, executive, and medical director services (including a detailed description of all tasks, duties, responsibilities, and accountabilities [TDRAs] related to the services to be performed);
2. All agreements for similar positions at the employer entity, including the scope of services to be performed under each of those agreements, the annual hour requirements, and annual compensation paid to each medical director;
3. Documentation regarding the board certification, qualifications, and tenure of those physicians performing services under all similar medical directorship agreements;
4. Documentation of offers made to previous (or other existing) medical directors;
5. Documentation regarding the medical staff’s need for administrative direction (based on clinical activities, hospital research efforts, community outreach programs, etc.);
6. The employer’s medical staff bylaws and roster;
7. Timesheet records and the time spent and work performed by the physician on each service subject to the medical directorship agreement;
8. The size of the employer, number of patients, acuity levels of patients, and the specific needs related to the particular service line;
9. The number of committees and meetings that require the medical director’s involvement and/or attendance, as well as the average frequency and duration of each committee and meeting;
10. Documentation that the employer (at least) annually assesses the effectiveness of the medical director in performing his or her TDRAs, as well as the commercial reasonableness of the contract; and,
11. Descriptions of quality programs, including centers of excellence and “never event” committees.

The review of these documents by the valuation analyst, as well as results from interviews with employer management and physicians, will serve as the basis for supporting the development of the certified opinion related to the scope of services to be performed.\(^14\)

The benchmarking of medical director services is similar to that of clinical services (discussed in the September 2016 Health Capital Topics article entitled, “Valuation of Compensation for Healthcare Services: Physician Clinical Services”), except that determination of the arrangement’s specific characteristics should also include:\(^15\)

1. Applicable job training and education level of the medical director that is relevant to the position;
2. The number of years of experience and reputation of the provider;
3. The size of the organization (e.g., revenue, number of employees);
4. The site of service (e.g., hospital, office-based physician practice, hospital service line, ambulatory surgery center); and,

© Health Capital Consultants

(Continued on next page)
(5) The geographic location where the subject services are to be provided.

While normative benchmark industry survey data can be used to establish FMV compensation rates, further analysis should be performed to meet the related threshold of commercial reasonableness. Significantly, even though a proposed compensation amount for medical director services may be deemed to be within the range of FMV, the TDRAs of the medical director should be analyzed to determine whether they are duplicate or redundant. Duplicate TDRAs are those that are exactly the same as TDRAs already being provided to the organization, the presence of which may not meet the threshold of being commercially reasonable. Redundant TDRAs are those that may be similar to TDRAs already being provided to the organization, but may be justified in those circumstances in which the size and scope of the organization require that higher level of service.27

A certified opinion as to whether the proposed compensation is both within the range of FMV and commercially reasonable, prepared by an independent, certified valuation professional, working with competent healthcare legal counsel as to the pertinent regulatory thresholds, and supported by adequate due diligence and documentation, will significantly enhance the efforts of healthcare providers to establish a defensible position that the proposed compensation arrangement is in compliance with all regulatory requirements.28 This is particularly important in the heightened and ever-changing regulatory environment in which healthcare providers operate, with the potential severity of penalties, as well as related business consequences for entering into transactions and arrangements that subsequently may be found to be legally impermissible.29

15 Ibid. p. 920.
16 Ibid.
17 Ibid.
19 Ibid.
23 Ibid. p. 213-214
24 ‘Never events’ are errors in medical care that are clearly identifiable, preventable, and serious in their consequences for patients,” thereby indicating a serious problem in the safety and credibility of the health care provider. Additionally, CMS indicated that such ‘never events,’ like surgery on the wrong body part or mismatched blood transfusion, cause serious injury or death to beneficiaries, and result in increased costs to the Medicare program to treat the consequences of the error.” “Eliminating Serious, Preventable, and Costly Medical Errors—Never Events,” Centers for Medicare & Medicaid Services, May, 18, 2006.
26 Ibid. p. 222.
28 Ibid. p. 927.
29 Ibid.“
Mr. Cimasi holds a Master in Health Administration from the University of Maryland, as well as several professional designations: Accredited Senior Appraiser (ASA – American Society of Appraisers); Fellow Royal Institution of Chartered Surveyors (FRICS – Royal Institution of Chartered Surveyors); Master Certified Business Appraiser (MCBA – Institute of Business Appraisers); Certified Valuation Analyst (CVA – National Association of Certified Valuators and Analysts); and, Certified Merger & Acquisition Advisor (CM&amp;A – Alliance of Merger & Acquisition Advisors). He has served as an expert witness on cases in numerous courts, and has provided testimony before federal and state legislative committees. He is a nationally known speaker on healthcare industry topics, and is the author of several books, the latest of which include: “The Adviser’s Guide to Healthcare – 2nd Edition” [2015 – AICPA]; “Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services” [2014 – John Wiley & Sons]; “Accountable Care Organizations: Value Metrics and Capital Formation” [2013 – Taylor & Francis, a division of CRC Press]; and, “The U.S. Healthcare Certificate of Need Sourcebook” [2005 - Beard Books].

Mr. Cimasi is the author of numerous additional chapters in anthologies; books, and legal treatises; published articles in peer reviewed and industry trade journals; research papers and case studies; and, is often quoted by healthcare industry press. In 2006, Mr. Cimasi was honored with the prestigious “Shannon Pratt Award in Business Valuation” conferred by the Institute of Business Appraisers. Mr. Cimasi serves on the Editorial Board of the Business Appraisals Practice of the Institute of Business Appraisers, of which he is a member of the College of Fellows. In 2011, he was named a Fellow of the Royal Institution of Chartered Surveyors (RICS). In 2016, Mr. Cimasi was named a “Pioneer of the Profession” as part of the recognition of the National Association of Certified Valuators and Analysts (NACVA) “Industry Titans” awards, which distinguishes those whom have had the greatest impact on the valuation profession.

Todd A. Zigrang, MBA, MHA, ASA, FACHE, is the President of Health Capital Consultants (HCC), where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 20 years of experience providing valuation, financial, transactional and strategic advisory services nationwide in over 1,000 transactions and joint ventures. Mr. Zigrang is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.

Mr. Zigrang is the co-author of “The Adviser’s Guide to Healthcare – 2nd Edition” [2015 – AICPA], numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: The Accountant’s Business Manual (AICPA); Valuing Professional Practices and Licenses (Aspen Publishers); Valuation Strategies; Business Appraisal Practice; and, NACVA QuickRead. In addition to his contributions as an author, Mr. Zigrang has served as faculty before professional and trade associations such as the American Society of Appraisers (ASA); the National Association of Certified Valuators and Analysts (NACVA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.

Mr. Zigrang holds a Master of Science in Health Administration (MHA) and a Master of Business Administration (MBA) from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives (FACHE) and holds the Accredited Senior Appraiser (ASA) designation from the American Society of Appraisers, where he has served as President of the St. Louis Chapter, and is current Chair of the ASA Healthcare Special Interest Group (HSIG).

John R. Chwarzinski, MSF, MAE, is Senior Vice President of Health Capital Consultants (HCC). Mr. Chwarzinski’s areas of expertise include advanced statistical analysis, econometric modeling, as well as, economic and financial analysis. Mr. Chwarzinski is the co-author of peer-reviewed and industry articles published in Business Valuation Review and NACVA QuickRead, and he has spoken before the Virginia Medical Group Management Association (VMGMA) and the Midwest Accountable Care Organization Expo.

Mr. Chwarzinski holds a Master’s Degree in Economics from the University of Missouri – St. Louis, as well as, a Master’s Degree in Finance from the John M. Olin School of Business at Washington University in St. Louis. He is a member of the St. Louis Chapter of the American Society of Appraisers, as well as a candidate for the Accredited Senior Appraiser designation from the American Society of Appraisers.

Jessica L. Bailey-Wheaton, Esq., is Vice President and General Counsel of Health Capital Consultants (HCC), where she conducts project management and consulting services related to the impact of both federal and state regulations on healthcare exempt organization transactions and provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services. Ms. Bailey is a member of the Missouri and Illinois Bars and holds a J.D., with a concentration in Health Law, from Saint Louis University School of Law, where she served as Fall Managing Editor for the Journal of Health Law & Policy.

Kenneth J. Farris, Esq., is an Associate at Health Capital Consultants (HCC), where he provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services, and tracks impact of federal and state regulations on healthcare exempt organization transactions. Mr. Farris is a member of the Missouri Bar and holds a J.D. from Saint Louis University School of Law, where he served as the 2014-2015 Footnotes Managing Editor for the Journal of Health Law & Policy.